Completed Digestion, Kidneys & Other Organs

Advanced Mineral-Bioactive Complex for Skin Barrier Optimisation for Psoriasis-Prone Skin

In plain English

AI plain-English summary

Psoriasis-prone skin in body folds often resists standard steroid creams, and Gran Lab’s new mineral-based formula aims to treat it without those drugs. This matters because sensitive psoriasis—affecting 3–7% of the 30 million psoriasis sufferers worldwide—is notoriously hard to treat. Existing options have side-effects: 70% of patients report a major negative impact on quality of life, 50% develop treatment resistance, and 35% face intimacy issues. People of colour are misdiagnosed 52% more often, leading to poorer care. The current gap is a steroid-free topical that works across diverse skin types. If GL-1 Mineral Complex Pro succeeds, it could offer a non-corrosive, non-irritant alternative that outperforms conventional hydrocortisone. The formulation has already shown anti-oxidant and anti-inflammatory properties in lab tests. Because Gran Lab tested it on a range of skin colours and textures, the product could reduce misdiagnosis-driven disparities and give clinicians a reliable option for patients who currently cycle through failing treatments.

View original technical description
Sensitive psoriasis is a challenging form of psoriasis that affects skin folds, making it difficult to treat. Of the 30million psoriasis sufferers worldwide, 3-7% have sensitive psoriasis. While there are several treatment options available, they often have limitations and side-effects, with 70% of patients reporting a major negative effect of their quality of life, 50% developing resistance to treatments, and 35% reporting higher rates of intimacy issues. Gran Lab are developing GL-1 Mineral Complex Pro, a novel steroid-free topical formulation which outperforms conventional hydrocortisone treatments and demonstrated non-corrosive, non-irritant, anti-oxidant, anti-inflammatory properties. Central to Gran Lab's ethos is equity of access to diverse skin types. People of colour face 52% higher misdiagnosis rates for psoriasis, and subsequently poorer or inadequate treatment regimens. Studies for GL-1 have purposefully accommodated a range of skin types, colours and textures to ensure outcomes are equally applicable to all communities.

View the original record at the funder ↗

Related Research

Grants with similar aims, by meaning.

Gran Lab Ltd.
MICA: Psoriasis Stratification to Optimise Relevant Therapy (PSORT)
AI-PSORT: Artificial Intelligence-enabled Psoriasis Stratification to Optimise Relevant Therapy
Identifying biomarkers of psoriasis-Driven Metabolic Disease
Clinical, genetic and immune determinants of drug immunogenicity in psoriasis

Original classification

Grant for R&D

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.